Literature DB >> 15522249

High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation.

Barbara J Caldarone1, Alexia Harrist, Muriel A Cleary, Robert D Beech, Sarah L King, Marina R Picciotto.   

Abstract

BACKGROUND: A wide variety of antidepressants act as noncompetitive antagonists of nicotinic acetylcholine receptors (nAChRs), but the relationship between this antagonism and the therapeutic effects of antidepressants is unknown.
METHODS: Antidepressant properties of the noncompetitive nAChR antagonist mecamylamine in the forced swim test were tested alone and in combination with the tricyclic antidepressant amitriptyline. Mice lacking high-affinity nAChRs were tested in three behavioral models to determine whether these receptors are required for behavioral effects of amitriptyline in common models of antidepressant action. Finally, the brains of wild-type and knockout animals treated with amitriptyline were examined to determine whether high-affinity nAChRs are required for antidepressant-induced increases in hippocampal cell proliferation.
RESULTS: Inhibition of nAChRs by mecamylamine had antidepressant-like effects in the forced swim test and potentiated the antidepressant activity of amitriptyline when the two drugs were used in combination. Mice lacking high-affinity nAChRs showed no behavioral response to amitriptyline. Finally, after chronic treatment with amitriptyline, nAChR knockout mice did not show the increase in hippocampal cell proliferation seen in wild-type mice.
CONCLUSIONS: These data support the hypothesis that antagonism of nAChRs is an essential component of the therapeutic action of antidepressants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522249     DOI: 10.1016/j.biopsych.2004.08.010

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  57 in total

1.  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.

Authors:  Li-Fang Yu; Werner Tückmantel; J Brek Eaton; Barbara Caldarone; Allison Fedolak; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-01-04       Impact factor: 7.446

Review 2.  Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature.

Authors:  Noah S Philip; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

Review 3.  Examining antidepressant drug response by smoking status: why is it important and how often is it done?

Authors:  Andrea H Weinberger; Sherry A McKee; Marina R Picciotto; Carolyn M Mazure
Journal:  J Psychopharmacol       Date:  2010-12-17       Impact factor: 4.153

4.  Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B.

Authors:  Yan Jiang; Mira Jakovcevski; Rahul Bharadwaj; Caroline Connor; Frederick A Schroeder; Cong L Lin; Juerg Straubhaar; Gilles Martin; Schahram Akbarian
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

5.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

6.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

7.  Social defeat, a paradigm of depression in rats that elicits 22-kHz vocalizations, preferentially activates the cholinergic signaling pathway in the periaqueductal gray.

Authors:  Roger A Kroes; Jeffrey Burgdorf; Nigel J Otto; Jaak Panksepp; Joseph R Moskal
Journal:  Behav Brain Res       Date:  2007-03-25       Impact factor: 3.332

Review 8.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

9.  Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II.

Authors:  Li-Fang Yu; J Brek Eaton; Allison Fedolak; Han-Kun Zhang; Taleen Hanania; Dani Brunner; Ronald J Lukas; Alan P Kozikowski
Journal:  J Med Chem       Date:  2012-11-02       Impact factor: 7.446

10.  Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant.

Authors:  Yang Yuan; Li-Fang Yu; Xi Qiu; Alan P Kozikowski; Richard B van Breemen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-11-23       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.